Last reviewed · How we verify
QBECO
At a glance
| Generic name | QBECO |
|---|---|
| Sponsor | Sunnybrook Health Sciences Centre |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver (PHASE2)
- QBECO SSI for Clinical and Endoscopic Remission in Moderate to Severe Crohn's Disease (PHASE2)
- Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis (PHASE2)
- Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QBECO CI brief — competitive landscape report
- QBECO updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI